Page last updated: 2024-11-06

hydrochlorothiazide-triamterene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Hydrochlorothiazide-triamterene is a combination medication used to treat high blood pressure (hypertension). It contains two drugs: hydrochlorothiazide, a thiazide diuretic, and triamterene, a potassium-sparing diuretic. Hydrochlorothiazide works by removing excess fluid and salt from the body through the urine, while triamterene helps to prevent the loss of potassium, which can be a side effect of hydrochlorothiazide. The combination of these two drugs can help to lower blood pressure more effectively than either drug alone. This combination is also studied to treat other conditions, such as heart failure, edema, and kidney stones. It's important to note that this medication can cause side effects, and should only be taken under the guidance of a healthcare professional.'

hydrochlorothiazide-triamterene: Russian drug; saluretic containing above 2 cpds; do not confuse with Triampur synonym for triamterene; Dyazide & Maxzide have different proportions [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID62940
SCHEMBL ID931483
MeSH IDM0366110

Synonyms (22)

Synonym
triamterene and hydrochlorothiazide
maxzide-25
triampur compositum
hydrochlorothiazide-triamterene
slimin
14124-50-6
hydrochlorathiazide-triamterene
triampur (combination)
dytide h
triamterene - hydrochlorothiazide mixt.
hydrochlorothiazide - triamterene mixt.
2h-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-, 1,1-dioxide, mixt. with 6-phenyl-2,4,7-pteridinetriamine
triamterene/hydrochlorothiazide
hydrochlorothiazide and triamterene
triamterene hydrochlorothiazide
triamterene / hctz
triamterene/hctz
novotriamazide
6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine- 7-sulfonamide, 1,1-dioxide, mixt. with 6-phenyl-2,4,7-pteridinetriamine
SCHEMBL931483
DTXSID50161615
6-chloro-1,1-dioxo-3,4-dihydro-2h-1lambda6,2,4-benzothiadiazine-7-sulfonamide;6-phenylpteridine-2,4,7-triamine

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Triamterin pharmacokinetic studies may be used for the screening of hypertensive patients as potential candidates for triampur treatment."( [Relation between the hypotensive effect of triampur and its pharmacokinetics in patients with hypertension].
Kuznetsov, GP; Lebedev, PA, 1986
)
0.27
" A pharmacokinetic characteristics of new drug adalate SL with two-step liberation of nifedipine."( [The pharmacokinetics of different drug forms of nifedipine when used singly and in a course as monotherapy and in combination with Cordanum and triampur preparations in patients with arterial hypertension].
Ignat'ev, VG; Kukes, VG; Pavlov, SS; Starodubtsev, AK,
)
0.13

Compound-Compound Interactions

ExcerptReferenceRelevance
" Good response was noted in corinfar-retard combination with Cordanum in patients with moderate hemodynamic changes, hypertonicity of sympathoadrenal system, tachycardia."( [The clinical efficacy of Korinfar-retard in combination with Cordanum, triampur and Capoten in patients with arterial hypertension].
Chil'tsov, VV; Ignat'ev, VG; Kukes, VG; Pavlov, SS; Pavlova, LI; Privalov, AN; Rumiantsev, AS, 1996
)
0.29

Bioavailability

ExcerptReferenceRelevance
"5 mg of triamterene) to one capsule of Dyazide (25 mg of hydrochlorothiazide and 50 mg of triamterene) to determine if the difference in bioavailability would be reflected in differences in blood pressure control and metabolic changes."( A comparison of the anti-hypertensive effectiveness of two triameterene/hydrochlorothiazide combinations: Maxzide versus Dyazide.
Casner, PR; Dillon, KR, 1990
)
0.28
" This reduced bioavailability may reduce its effectiveness in hypertensive patients who change from optimally bioavailable hydrochlorothiazide tablets to Dyazide capsules in an effort to correct hypokalemia."( A new antihypertensive agent: Maxzide (75 mg triamterene/50 mg hydrochlorothiazide).
Blume, CD; Williams, RL, 1984
)
0.27
" The clinical consequences of the limited bioavailability of the active ingredients of Dyazide are discussed."( Bioequivalence study of a new tablet formulation of triamterene and hydrochlorothiazide.
Benet, LZ; Blume, CD; Lin, ET; Upton, RA; Williams, RL, 1984
)
0.27
" Statistical comparison showed that the test and reference products were bioequivalent in terms of both the rate and extent of bioavailability of both active ingredients."( Bioequivalence evaluation of a triamterene-hydrochlorothiazide generic product: a new bioequivalence index for fixed-dose combinations.
Azimi, K; Hamidi, M; Shahbazi, MA, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (54)

TimeframeStudies, This Drug (%)All Drugs %
pre-199042 (77.78)18.7374
1990's7 (12.96)18.2507
2000's1 (1.85)29.6817
2010's4 (7.41)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 78.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index78.23 (24.57)
Research Supply Index4.32 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index133.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (78.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (27.59%)5.53%
Reviews3 (5.17%)6.00%
Case Studies15 (25.86%)4.05%
Observational0 (0.00%)0.25%
Other24 (41.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Action to Control Cardiovascular Risk in Diabetes (ACCORD) [NCT00000620]Phase 310,251 participants (Actual)Interventional1999-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00000620 (6) [back to overview]Death From Any Cause in the Glycemia Trial.
NCT00000620 (6) [back to overview]First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.
NCT00000620 (6) [back to overview]First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.
NCT00000620 (6) [back to overview]First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.
NCT00000620 (6) [back to overview]Stroke in the Blood Pressure Trial.

Death From Any Cause in the Glycemia Trial.

"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years

Interventionparticipants (Number)
Glycemia Trial: Intensive Control391
Glycemia Trial: Standard Control327

[back to top]

First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.

"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years

Interventionparticipants (Number)
Glycemia Trial: Intensive Control503
Glycemia Trial: Standard Control543

[back to top]

First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
BP Trial: Intensive Control208
BP Trial: Standard Control237

[back to top]

First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
Lipid Trial: Fenofibrate291
Lipid Trial: Placebo310

[back to top]

First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
Lipid Trial: Fenofibrate641
Lipid Trial: Placebo667

[back to top]

Stroke in the Blood Pressure Trial.

Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
BP Trial: Intensive Control36
BP Trial: Standard Control62

[back to top]